CITATION REPORT List of articles citing



DOI: 10.1161/circulationaha.115.008722 Circulation, 2016, 133, 2076-85.

Source: https://exaly.com/paper-pdf/63939641/citation-report.pdf

Version: 2024-04-18

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
101	Letter by Antignac et al Regarding Article "Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries". <i>Circulation</i> , 2016 , 134, e303-e304	16.7	1
100	Could patents interfere with the development of a cardiovascular polypill?. 2016, 14, 242		7
99	Prevalence and prevention of cardiovascular disease and diabetes mellitus. 2016 , 113, 600-609		227
98	Response by Wirtz et al to Letter Regarding Article, "Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries". <i>Circulation</i> , 2016 , 134, e305-e306	16.7	
97	Do We Need a New Definition of Hypertension After SPRINT?. 2016 , 29, 1127-9		10
96	Reducing the Global Burden of Cardiovascular Disease, Part 2: Prevention and Treatment of Cardiovascular Disease. 2017 , 121, 695-710		134
95	Availability, Sales, and Affordability of Tobacco Cessation Medicines in Kerala, India. 2017 , 10,		6
94	Fighting fake medicines: First quality evaluation of cardiac drugs in Africa. 2017, 243, 523-528		26
93	Consumer quality use of medicines: An important element in public health. 2017 , 13, 261-265		2
92	Ensuring Patient-Centered Access to Cardiovascular Disease Medicines in Low-Income and Middle-Income Countries Through Health-System Strengthening. 2017 , 35, 125-134		15
91	Addressing the cost of infractions in the online literature and databases. 2017 , 12, e0188761		
90	Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases. 2018 , 71, 564-574		21
89	Socioeconomic Status and Hypertension Control in Sub-Saharan Africa: The Multination EIGHT Study (Evaluation of Hypertension in Sub-Saharan Africa). 2018 , 71, 577-584		27
88	Recommended treatment protocols to improve management of hypertension globally: A statement by Resolve to Save Lives and the World Hypertension League (WHL). 2018 , 20, 829-836		18
87	Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial. 2018 , 262, 71-78		7
86	Burden of cardiovascular diseases in the Eastern Mediterranean Region, 1990-2015: findings from the Global Burden of Disease 2015 study. 2018 , 63, 137-149		40
85	Barriers to Global Action Plan for the Prevention and Control of Noncommunicable Diseases: Proposal Modifications to the Voluntary Targets. 2018 , 03,		5

(2019-2018)

84	Access to Antihypertensive Medicines at the Household Level: A Study From 8 Counties of Kenya. 2018 , 13, 247-253.e5	3
83	Interpreting the various associations of MiRNA polymorphisms with susceptibilities of cardiovascular diseases: Current evidence based on a systematic review and meta-analysis. 2018 , 97, e10712	3
82	Unmodifiable events, heart failure research, and Sisk-based monitoringSin large studies-the unholy triumvirate. 2018 , 20, 1639-1644	5
81	Mobile Personal Health Monitoring for Automated Classification of Electrocardiogram Signals in Elderly. 2018 , 2018, 9128054	21
80	Burden of Ischaemic heart disease and attributable risk factors in China from 1990 to 2015: findings from the global burden of disease 2015 study. 2018 , 18, 18	27
79	The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1 million adults. 2019 , 394, 652-662	149
78	Factors associated with poor adherence to medication among hypertensive patients in twelve low and middle income Sub-Saharan countries. 2019 , 14, e0219266	23
77	Studies of Drug Utilization. 2019 , 373-410	2
76	Attributable Burden and Expenditure of Cardiovascular Diseases and Associated Risk Factors in Mexico and other Selected Mega-Countries. 2019 , 16,	6
75	Falsified and substandard cardiovascular drugs in Africa: a need for continued monitoring strategies. 2019 , 9, 010302	1
74	Identifying a human rights-based approach to obesity for States and civil society. 2019 , 20 Suppl 2, 45-56	6
73	Six Month Polypill Therapy Improves Lipid Profile in Patients with Previous Acute Myocardial Infarction: The Heart-Mex Study. 2019 , 50, 197-206	7
72	Global Updates on Cardiovascular Disease Mortality Trends and Attribution of Traditional Risk Factors. 2019 , 19, 44	76
71	Combatting the Global Crisis of Cardiovascular Disease. 2019 , 28, 981-983	2
70	Estrategias para promover el acceso a medicamentos de inter¶ en salud pBlica: revisiB estructurada de la literatura. 2019 , 38,	1
69	Income level and inequality as complement to geographical differences in cardiovascular trials. 2019 , 218, 66-74	12
68	Access to medicines through health systems in low- and middle-income countries. 2019, 34, iii1-iii3	22
67	Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon. 2019 , 19, 973	5

66	Access to essential cardiovascular medicines for children: a pilot study of availability, price and affordability in Nigeria. 2019 , 34, iii20-iii26	3
65	Medication adherence and predictive factors in patients with cardiovascular disease: A comparison study between Australia and Iraq. 2019 , 26, 355-365	4
64	Solving the problem of access to cardiovascular medicines: revolving fund pharmacy models in rural western Kenya. 2020 , 5,	6
63	Prediction of Chronic Diseases With Multi-Label Neural Network. 2020 , 8, 138210-138216	5
62	Consumption and Lack of Access to Medicines and Associated Factors in the Brazilian Amazon: A Cross-Sectional Study, 2019. 2020 , 11, 586559	5
61	Why healthcare market needs government intervention to improve access to essential medicines and healthcare efficiency: a scoping review from pharmaceutical price regulation perspective. 2020 , 11, 321-333	1
60	Systemic Solutions for Addressing Non-Communicable Diseases in Low- and Middle-Income Countries. 2020 , 13, 693-707	8
59	An overview of heart failure in low- and middle-income countries. 2020 , 10, 244-251	13
58	Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability. 2020 , 9, e015302	24
57	Prevalence and Determinants of Hypertension Awareness, Treatment, and Control in Botswana: A Nationally Representative Population-Based Survey. 2020 , 2020, 8082341	6
56	Affordability Assessment from a Static to Dynamic Concept: A Scenario-Based Assessment of Cardiovascular Medicines. 2020 , 17,	3
55	Cardiometabolic Risk Factors in Pregnancy and Implications for Long-Term Health: Identifying the Research Priorities for Low-Resource Settings. 2020 , 7, 40	5
54	Review of Ongoing Activities and Challenges to Improve the Care of Patients With Type 2 Diabetes Across Africa and the Implications for the Future. 2020 , 11, 108	43
53	Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction. 2021 , 322, 183-190	12
52	Access to Essential Cardiovascular Medicines in Pakistan: A National Survey on the Availability, Price, and Affordability, Using WHO/HAI Methodology. 2020 , 11, 595008	3
51	Trends in Cardiovascular Medicine Use in 65 Middle- and High-Income Countries. 2021 , 77, 1021-1023	4
50	Cardioprotective Effect of Crude Extract and Solvent Fractions of Leaves on Cyclophosphamide-Induced Myocardial Injury in Rats. 2021 , 13, 147-160	5
49	Strategies to improve the availability of medicines in primary health care in Brazil: findings and implications. 2021 , 10, 243-253	1

48	Reasons for poor blood pressure control in Eastern Sub-Saharan Africa: looking into 4Ps (primary care, professional, patient, and public health policy) for improving blood pressure control: a scoping review. 2021 , 21, 123	3
47	Comparative Efficacy and Safety of Ultra-Long-Acting, Long-Acting, Intermediate-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: a Systematic Review and Network Meta-Analysis. 2021 , 36, 2414-2426	7
46	Availability and affordability of children essential medicines in health facilities of southern nations, nationalities, and people region, Ethiopia: key determinants for access. 2021 , 21, 714	2
45	Availability, Affordability, Access, and Pricing of Anti-cancer Medicines in Low- and Middle-Income Countries: A Systematic Review of Literature. 2021 , 9, 628744	11
44	The importance of considering cultural and environmental elements in an interventional model of care to fight hypertension in Africa. 2021 , 23, 1269-1270	2
43	Health care reform and stroke prognosis in low-income Chinese populations from 1992 to 2018. 2021 , 11, 08002	2
42	Influence of pharmaceutical services organization on the availability of essential medicines in a public health system. 2021 , 10, 519-532	1
41	Health System Capacity and Access Barriers to Diagnosis and Treatment of CVD and Diabetes in Nepal. 2021 , 16, 38	1
40	Social Determinants of Health and Comorbidities Among Individuals with Atherosclerotic Cardiovascular Disease: The Behavioral Risk Factor Surveillance System Survey. 2021 ,	2
39	Sex differences in mortality after an acute coronary syndrome increase with lower country wealth and higher income inequality. 2021 ,	
38	Evaluation of a package of risk-based pharmaceutical and lifestyle interventions in patients with hypertension and/or diabetes in rural China: A pragmatic cluster randomised controlled trial. 2021 , 18, e1003694	1
37	Inventory Management Practices in Private Healthcare Facilities in Nairobi County.	O
36	Las diferencias por sexo en la mortalidad tras un sīldrome coronario agudo se incrementan en los paßes de menor riqueza y mayor desigualdad de ingresos. 2021 ,	О
35	Sunlight powered degradation of pentoxifylline CsLiFeO as a green reusable photocatalyst: Mechanism, kinetics and toxicity studies. 2021 , 416, 125762	13
34	Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement (NVBP) effect in China. 2021 , 6,	1
33	Cardiovascular Health and The Intestinal Microbial Ecosystem: The Impact of Cardiovascular Therapies on The Gut Microbiota. 2021 , 9,	3
32	64 PI/PDMS hybrid cantilever arrays with an integrated strain sensor for a high-throughput drug toxicity screening application. 2021 , 190, 113380	5
31	Indicator of access to medicines in relation to the multiple dimensions of access. 2019 , 8, 1027-1041	10

Outpatient cardiovascular diseases and diabetes medicines dispensing in the population with 30 government health insurance in Syria between 2018 and 2019: a retrospective analysis. 2021, 21, 1088 Approaches to Clinical Development of Combination Medicines in the Russian Federation and the 29 Eurasian Economic Union in view of the Requirements of the Current Legislation. 2019, 9, 14-27 An Empirical Analysis of Demand-Supply Mismatches in Private Healthcare Facilities in Nairobi 28 County. Challenges in Pharmacological Management of Cardiovascular Diseases in Covid-19: do Benefits 27 Outweigh Risks?. **2020**, 33, 404-411 26 Update on Hypertension Epidemiology. 2020, 19, 32-42 Clinical Characteristics and Prognosis of Young Patients with Coronary Heart Disease. 2020, 26, e922957 25 Medicines Availability among Hypertensive Patients in Primary Health Care Facilities in a Rural 24 Province in South Africa: Findings and Implications. 2020, 9, 181-185 Utilization, Cost, and Affordability of Antihypertensive Therapy in Bulgaria. 2021, 20, 403-416 23 Application of Metabolomics to Identify Potential Biomarkers for the Early Diagnosis of Coronary О 2.2 Heart Disease.. 2021, 12, 775135 Blood pressure-lowering medicines implemented in 12 African countries: the cross-sectional multination EIGHT study. 2021, 11, e049632 Reimagining the Nigerian Healthcare System to Achieve Universal and High-Quality Health Care by 20 2030. 2021, 407-454 The use of pulmonary arterial hypertension therapies in Eisenmenger syndrome.. 2021, 1-9 19 Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and 18 meta-analysis of cost-utility studies. Integrated multi-month dispensing of antihypertensive and antiretroviral therapy to sustain 17 hypertension and HIV control.. 2022, Availability and Affordability of Medicines for Diabetes and Cardiovascular Disease across 16 O Countries: Information Learned from the Prospective Urban Rural Epidemiological Study. 2022, 3, 236-245 Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income 6 15 countries: a cross-sectional study of nationally representative, individual-level data.. 2022, 10, e369-e379 Factors associated with the availability and affordability of essential cardiovascular disease 14 medicines in low- and middle-income countries: A systematic review. 2022, 2, e0000072 DataSheet_1.docx. 2020, 13

12 DataSheet_2.docx. 2020,

11	Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies. 2022 , 17, e0264563	O
10	Drug shortages in low- and middle-income countries: Colombia as a case study. 2022, 15,	0
9	Barriers to up-titrated antihypertensive strategies in 12 sub-Saharan African countries: the Multination Evaluation of hypertension in Sub-Saharan Africa Study. Publish Ahead of Print,	
8	Barriers and Facilitators in Access to Diabetes, Hypertension, and Dyslipidemia Medicines: A Scoping Review. 43,	1
7	Community-based medication delivery program for antihypertensive medications improves adherence and reduces blood pressure. 2022 , 17, e0273655	O
6	Investigating the Role of Endothelial Glycogen Synthase Kinase3ص Atherogenesis in Low Density Lipoprotein Receptor Knockout Mice. 2022 , 23, 14780	О
5	Changes in the burden and underlying causes of heart failure in the Eastern Mediterranean Region, 1990 2 019: An analysis of the Global Burden of Disease Study 2019. 2023 , 56, 101788	O
4	Patient Access to Medical Insurance Covered Orphan Drugs in China: Real-World Evidence From Patient Survey. 2023 , 34, 71-77	0
3	Utilizing quantitative dried blood spot analysis to objectively assess adherence to cardiovascular pharmacotherapy among patients at Kenyatta National Hospital, Nairobi, Kenya. 2023 , 18, e0280137	O
2	The mediation effects of metabolic and immuneInflammation factors on the depressionBremature coronary heart disease association. 2023 , 331, 434-441	0
1	Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US.	O